MX2016009751A - Agente mejorador del efecto de la rehabilitacion despues de una lesion nerviosa que comprende un derivado de eter de alquilo o una sal del mismo. - Google Patents

Agente mejorador del efecto de la rehabilitacion despues de una lesion nerviosa que comprende un derivado de eter de alquilo o una sal del mismo.

Info

Publication number
MX2016009751A
MX2016009751A MX2016009751A MX2016009751A MX2016009751A MX 2016009751 A MX2016009751 A MX 2016009751A MX 2016009751 A MX2016009751 A MX 2016009751A MX 2016009751 A MX2016009751 A MX 2016009751A MX 2016009751 A MX2016009751 A MX 2016009751A
Authority
MX
Mexico
Prior art keywords
salt
alkyl ether
enhancing agent
nerve injury
ether derivative
Prior art date
Application number
MX2016009751A
Other languages
English (en)
Inventor
Takahashi Takuya
Okuda Tomohiro
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of MX2016009751A publication Critical patent/MX2016009751A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin
    • A61K9/5057Gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona una composición medicinal caracterizada porque comprende un derivado de éter de alquilo representado por la fórmula general [1] (ver Fórmula) en donde R1 y R2 son los mismos o diferentes y representan un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C1-6 opcionalmente sustituido, un grupo arilo opcionalmente sustituido, etc.; R3 representa un grupo hidroxilo opcionalmente protegido; etc., y m y n son los mismos o diferentes, y representan un número entero desde 1 hasta 6] o una sal del mismo. La composición medicinal de acuerdo con la presente invención es útil como un agente mejorador del efecto de la rehabilitación después de una lesión nerviosa.
MX2016009751A 2014-01-31 2015-01-30 Agente mejorador del efecto de la rehabilitacion despues de una lesion nerviosa que comprende un derivado de eter de alquilo o una sal del mismo. MX2016009751A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014017587 2014-01-31
PCT/JP2015/052617 WO2015115582A1 (ja) 2014-01-31 2015-01-30 アルキルエーテル誘導体またはその塩を含有する神経損傷後のリハビリテーション効果促進剤

Publications (1)

Publication Number Publication Date
MX2016009751A true MX2016009751A (es) 2016-11-08

Family

ID=53757150

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009751A MX2016009751A (es) 2014-01-31 2015-01-30 Agente mejorador del efecto de la rehabilitacion despues de una lesion nerviosa que comprende un derivado de eter de alquilo o una sal del mismo.

Country Status (26)

Country Link
US (2) US10039744B2 (es)
EP (1) EP3100725B1 (es)
JP (3) JP5837726B1 (es)
KR (1) KR102346219B1 (es)
CN (1) CN106061478B (es)
AU (1) AU2015211753B2 (es)
BR (1) BR112016017747A2 (es)
CA (1) CA2938184C (es)
CY (1) CY1123154T1 (es)
DK (1) DK3100725T3 (es)
ES (1) ES2792950T3 (es)
HR (1) HRP20200796T1 (es)
HU (1) HUE050400T2 (es)
IL (1) IL246925B (es)
LT (1) LT3100725T (es)
MX (1) MX2016009751A (es)
MY (1) MY179290A (es)
PH (1) PH12016501507A1 (es)
PL (1) PL3100725T3 (es)
PT (1) PT3100725T (es)
RS (1) RS60462B1 (es)
RU (1) RU2680247C2 (es)
SG (2) SG11201606173TA (es)
SI (1) SI3100725T1 (es)
SM (1) SMT202000395T1 (es)
WO (1) WO2015115582A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016017747A2 (pt) * 2014-01-31 2017-08-08 Toyama Chemical Co Ltd Agente de intensificação de efeito de reabilitação pós lesão de nervo compreendendo derivados de éter de alquila ou sal do mesmo
CA3009152C (en) 2015-12-25 2023-08-15 Toyama Chemical Co., Ltd. Tablet comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof
JP7057286B2 (ja) * 2016-12-28 2022-04-19 富士フイルム富山化学株式会社 医薬組成物
CN110121342A (zh) * 2016-12-28 2019-08-13 富士胶片富山化学株式会社 医药组合物
US20190343796A1 (en) * 2016-12-28 2019-11-14 Fujifilm Toyama Chemical Co., Ltd. Composition for external use
US11234962B2 (en) 2016-12-28 2022-02-01 Fujifilm Toyama Chemical Co., Ltd. Pharmaceutical composition and method of manufacturing the same
CA3067455C (en) * 2017-06-02 2021-11-23 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
JP7370859B2 (ja) * 2017-06-02 2023-10-30 富士フイルム富山化学株式会社 タウオパチー予防または治療剤
KR20190137936A (ko) * 2017-06-02 2019-12-11 후지필름 도야마 케미컬 가부시키가이샤 뇌 위축 예방 또는 치료제
US11541033B2 (en) 2017-06-02 2023-01-03 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating Alzheimer's disease
MX393006B (es) * 2017-06-02 2025-03-24 Fujifilm Toyama Chemical Co Ltd Agente para reducir la cantidad de proteina beta amiloide.
JP7227914B2 (ja) 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0213393B8 (pt) * 2001-10-19 2021-05-25 Fujifilm Toyama Chemical Co Ltd derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
WO2003045137A1 (fr) * 2001-11-29 2003-06-05 Japan Science And Technology Agency Procede de construction d'un modele simien de lesion spinale et son utilisation
HUE041842T2 (hu) 2002-06-14 2019-05-28 Toyama Chemical Co Ltd Gyógyászati készítmény agymûködés javítására
ES2391273T3 (es) 2003-04-17 2012-11-23 Toyama Chemical Co., Ltd. Agente preventivo/curativo para enfermedades del nervio retiniano que contiene derivados de éter alquílico o sus sales
SI2248809T1 (sl) 2005-03-28 2012-09-28 Toyama Chemical Co Ltd Alkil-3-(2-(benzo(b)tiofen-5-il)-etoksi)-propanoati kot vmesniki v proizvodnji derivatov azetidin-3-ola
RU2397169C2 (ru) * 2005-03-28 2010-08-20 Тояма Кемикал Ко., Лтд. Способ получения 1-(3-(2-(1-бензотиофен-5-ил)этокси) пропил)азетидин-3-ола или его солей
CA2648898C (en) * 2006-04-26 2015-01-20 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
BR112016017747A2 (pt) * 2014-01-31 2017-08-08 Toyama Chemical Co Ltd Agente de intensificação de efeito de reabilitação pós lesão de nervo compreendendo derivados de éter de alquila ou sal do mesmo

Also Published As

Publication number Publication date
JP6642914B2 (ja) 2020-02-12
NZ722542A (en) 2021-07-30
PH12016501507A1 (en) 2017-02-06
RU2016135236A (ru) 2018-03-02
PL3100725T3 (pl) 2020-11-16
HK1226298A1 (en) 2017-09-29
AU2015211753B2 (en) 2019-09-12
CA2938184A1 (en) 2015-08-06
SI3100725T1 (sl) 2020-08-31
US20180289668A1 (en) 2018-10-11
SMT202000395T1 (it) 2020-09-10
US10039744B2 (en) 2018-08-07
JP5837726B1 (ja) 2015-12-24
JP2016074676A (ja) 2016-05-12
EP3100725B1 (en) 2020-05-06
DK3100725T3 (da) 2020-06-22
IL246925A0 (en) 2016-09-29
RS60462B1 (sr) 2020-07-31
MY179290A (en) 2020-11-03
CA2938184C (en) 2021-11-23
JPWO2015115582A1 (ja) 2017-03-23
CY1123154T1 (el) 2021-10-29
RU2016135236A3 (es) 2018-08-30
SG11201606173TA (en) 2016-08-30
HRP20200796T1 (hr) 2020-08-07
KR102346219B1 (ko) 2022-01-04
US20170165227A1 (en) 2017-06-15
IL246925B (en) 2019-10-31
WO2015115582A1 (ja) 2015-08-06
JP2020073542A (ja) 2020-05-14
HUE050400T2 (hu) 2020-12-28
AU2015211753A1 (en) 2016-08-11
EP3100725A1 (en) 2016-12-07
RU2680247C2 (ru) 2019-02-19
EP3100725A4 (en) 2017-08-30
PT3100725T (pt) 2020-06-17
BR112016017747A2 (pt) 2017-08-08
CN106061478B (zh) 2019-04-30
ES2792950T3 (es) 2020-11-12
LT3100725T (lt) 2020-08-10
SG10201907035TA (en) 2019-09-27
CN106061478A (zh) 2016-10-26
US10471044B2 (en) 2019-11-12
KR20160113281A (ko) 2016-09-28
JP6825074B2 (ja) 2021-02-03

Similar Documents

Publication Publication Date Title
PH12016501507A1 (en) Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof
JOP20200225A1 (ar) مشتق كوينولين عالي النقاء وطريقة لإنتاجه
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12014502866A1 (en) Fungicidal heterocyclic carboxamides
TN2015000245A1 (en) Heterocyclic compound
PH12022552034A1 (en) Pyridone derivative having tetrahydropyranyl methyl group
MX376283B (es) Compuestos de imidazopiridazina.
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
DOP2020000118A (es) Proceso para la preparación de derivados de quinolina
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
CL2017000103A1 (es) Derivados de bis(aril)catecol como herbicidas
CY1121626T1 (el) Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου
MX2019004294A (es) Derivados de fenilamina 4-sustituidos y su uso para proteger cultivos al combatir microorganismos fitopatogenicos indeseados.
MY170262A (en) Dicarboxylic acid compound
NZ703217A (en) Novel cyclic depsipeptide derivatives and harmful organism control agents comprising the same
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
JO3264B1 (ar) مركبات ازيتيدينيل أوكسي فينيل بيروليدين
PH12018500668A1 (en) Therapeutic compounds and methods of use thereof
MX2019004293A (es) Derivados de fenilamina sustituidos en la posicion 4 y uso de los mismos para proteger los cultivos combatiendo los microorganismos fitopatogenos no deseados.
UA111950C2 (uk) Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX2015010790A (es) Derivados de anilina sustituidos con n-heteroarilo como antivirales de vhc.
MX368759B (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
MX2017001320A (es) Amidas del acido arilcarboxilico biciclicas y su uso como herbicidas.
MX377963B (es) Composición acuosa.

Legal Events

Date Code Title Description
FG Grant or registration